Skip to content
10-Q

Quarterly Report

DRUGS MADE IN AMERICA ACQUISITION CORP. DMAA DMAAR DMAAU

0001213900-25-076681

← back to feed
Filed
Aug 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 14, 2025 33.52M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$357.9K
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$114.93K
Stockholders Equity Q2 2025 · Jun 30, 2025 −$7.15M
Stockholders Equity Q2 2025 · Mar 31, 2025 −$7.18M
Stockholders Equity Q2 2025 · Dec 31, 2024 −$244.85K
Stockholders Equity Q2 2025 · Jun 30, 2024 −$19.93K
Current Liabilities Q2 2025 · Jun 30, 2025 $301.44K
Current Liabilities Q2 2025 · Dec 31, 2024 $795.67K
Total Liabilities Q2 2025 · Jun 30, 2025 $7.2M
Total Liabilities Q2 2025 · Dec 31, 2024 $795.67K
Current Assets Q2 2025 · Jun 30, 2025 $49.73K
Current Assets Q2 2025 · Dec 31, 2024 $4.99K
Total Assets Q2 2025 · Jun 30, 2025 $235.21M
Total Assets Q2 2025 · Dec 31, 2024 $550.82K
Sga Expense Q2 2025 · Jun 30, 2025 $131.92K
Sga Expense Q2 2025 · Jun 30, 2025 $462.84K
Sga Expense Q2 2025 · Jun 30, 2024 $54.93K
Net Income Q2 2025 · Jun 30, 2025 $2.29M
Net Income Q2 2025 · Jun 30, 2025 $3.54M
Net Income Q2 2025 · Mar 31, 2025 $1.25M
Net Income Q2 2025 · Jun 30, 2024 −$54.93K
Operating Income Q2 2025 · Jun 30, 2025 −$131.92K
Operating Income Q2 2025 · Jun 30, 2025 −$462.84K
Operating Income Q2 2025 · Jun 30, 2024 −$54.93K